Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent (dupilumab) in adults ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent in adults with moderate-to-severe ...

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chronic obstructive ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating moderate-to-severe bullous pemphigoid (BP). The findings were presented at the 2025 ...

After hours: March 12 at 7:11:55 PM EDT Loading Chart for PI ...

PI Industries Ltd., incorporated in the year 1946, is a Large Cap company (having a market cap of Rs 50,026.02 Crore) operating in Pesticides/Agro Chemicals sector. PI Industries Ltd. key ...